|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Orphan Vaccines - Bridging the Gap | ||||||||||||||||
| March 13, 2001 | ||||||||||||||||
|
International Association for Biological Standardization (IABS), Palm Cove, Queensland, Australia 25-29 August 2001 What happens when there is no commercial sponsor for an innovative new vaccine? There are many ‘Orphan Vaccines' in the early phase of development (eg. for HIV/AIDS, malaria, and rheumatic fever) many of which will be used, primarily in developing countries. This conference will address the technical, regulatory and financial obstacles to vaccine development, with a view to facilitating the transition from basic immunology to an effective product. Following the presentation of two specific case studies, malaria and HIV/AIDS, specific topics that will be addressed will include the prevention of pandemic influenza, the development of vaccines against potential biological warfare agents, and vaccines against Epstein Barr Virus (EBV), Cytomegalovirus (CMV), hydatid disease, meningococcal disease and rheumatic fever. Innovative models of vaccine development and financing will be presented and discussed. Saturday, 25th August 2001 1500-1700 Registration 1700-1800 Meeting Opening, Welcome & Overview Chair: Ian Gust (AU) Meeting objectives/outcomes sought Anne Kelso (CRC-VT) Welcome from the CRC-VT John Petricciani (IABS) Welcome from the IABs 1800 Meeting Mixer / Welcome Reception Sunday 26th August 2001 0900-1030 Session 1: Scientific and technical obstacles Chair: Ian Gust (AU) Trevor Trust (USA) The identification of protective antigens using modern techniques, opportunities and challenges Gary van Nest (USA) Challenges in inducing a balanced immune response especially induction of CMI Ron Ellis (USA) Challenges, skills and costs of producing modern vaccines based on rDNA technology. Special problems of transferring technology and production to the developing world. 1030-1100 Morning Tea 1100-1230 Session 2: Financial obstacles Chair: Gus Nossal (AU) Amy Batson (USA) The costs and economics of modern vaccine development Francis Andre (Belgium) How the research based industry approaches vaccine development and establishing priorities Sunheang Shin (Korea) The generic vaccine business 1230-1400 Lunch 1400-1530 Session 3: The malaria case study Chair: Michael Good (AU) Graham Brown (AU) The extent of the problem, historical attempts at control and their limitations, reasons for believing immunisation may be successful, the potential of new drugs and vaccines Robin Anders (AU) Current approaches to vaccine development; what is needed to move them forward Regina Rabinovitch (USA) The Malaria Vaccine Initiative 1530-1600 Afternoon Tea 1600-1730 Session 4: The AIDS case study Chair: Chris Puplick ANCHARD (AU) Peter McDonald (AU) Outline current and future problem, approaches to control and their limitations the potential for new drugs and vaccines Peggy Johnson (USA) Overview of current approaches to vaccine development and what is needed to drive them forward Jaap Goudsmit (Netherlands) International and national initiatives Monday, 26th August 2001 Networking day Outer Great Barrier Reef Experience, for Conference Attendees as well as Accompanying Persons Tuesday, 27th August 2001 0830-1030 Session 5: Orphan vaccines in early development Chair: Anne Kelso (AU) Dennis Moss (AU) Epstein-Barr Virus vaccines Michael Good (AU) Group A Streptococci vaccines Marshall Lightowlers (AU) Echinococcus granulosis vaccine 1030-1100 Morning Tea 1100-1230 Session 6: Vaccines against biological warfare agents Chair: Stanley Plotkin (USA) Andy Robertson (AU) Reasons for believing these vaccines are needed Kathy Zoon (USA) The regulatory status of currently available vaccines which could be used to protect against these threats Michael Langford (USA) Difficulties associated with upgrading licensed and effective vaccines licensed many years ago 1230-1400 Lunch 1400-1530 Session 7: Pandemic influenza Chair: Dick Smallwood (AU) Alan Hampson (AU) History, extent of the problem, approaches to control Ron Ellis (USA) Production issues in rapidly expanding production capacity, eggs v TC, etc Kathy Coelingh (USA) An attempt to establish seed viruses containing novel avian HA and NA antigens prior to the emergence of the next pandemic strain 1530-1600 Afternoon Tea 1600-1730 Session 8: Regulatory barriers to new vaccine development...thinking outside the box Chair: John Petricciani IABS (round table) Geoffrey Schild (UK) Wayne Koff (USA) Johannes Loewer (Germany) Elwyn Griffiths (Switzerland) Peggy Johnston (USA) Grahame Dickson (AU) Roy Widdus (Switzerland) Kathy Zoon (USA) 1930 Conference Dinner Wednesday 28th August, 2001 0830-1000 Session 9: Innovative Approaches Chair: Dick Strugnell (AU) Mark Kane (USA) The Gates program Wayne Koff (USA) IAVI history, evolution, structure challenges Jaap Goudsmit (Netherlands) Process for identification of targets, establishing priorities for support, and managing vaccine development in a virtual organisation, issues and lessons. 1000-1030 Morning Tea 1030-1200 Session 10: Other barriers to developing or introducing new vaccines Chair: Gus Nossal (AU) John Clemens (Korea) The need for good local epidemiological data to guide decisions and priorities, the role of the IVI Supamit Chunsuttiwat (Indonesia) The importance of local factors, training, motivation, logistics, communications etc. Amy Baston (USA) Sustainable funding - options being canvassed Closing remarks: Gus Nossal (AU) |
||||||||||||||||
| Organized by: | Cooperative Research Centre for Vaccine Technology | |||||||||||||||
| Invited Speakers: | Ian Gust (AU) Anne Kelso (AU) John Petricciani (USA) Trevor Trust (USA) Ron Ellis (USA) Gus Nossal (AU) Amy Batson (USA) Francis Andre (Belgium) Sunheang Shin (Korea) Michael Good (AU) Regina Rabinovich (USA) Chris Puplick (AU) Peter MacDonald (AU) Peggy Johnston (USA Jaap Goudsmit (NL) Stanley Plotkin (USA) David Salisbury (UK) Kathy Zoon (USA) Michael Langford Dick Smallwood (AU) Kathy Coelingh (USA) Geoffrey Schild (UK) Johannes Loewer (Germany) Roy Widdus (Switzerland) Wayne Koff (USA) Elwyn Griffiths (Switzerland) Grahame Dickson (AU) Gordon Dougan (UK) Mark Kane (USA) John Clemens (Korea) Supamit Chunsuttiwat (Indonesia) |
|||||||||||||||
| Deadline for Abstracts: | Invited abstracts only | |||||||||||||||
| Registration: | Delegate Registration Fee includes: Welcome Reception, conference Dinner, attendance at all sessions, morning & afternoon tea and lunch on session days, printed program. AUD$750.00 Accommodation and flights are extra. Register on-line. |
|||||||||||||||
| E-mail: | michele@orphan-vaccines-conference.com | |||||||||||||||
| Posted by: | Clare Peddie | |||||||||||||||
| Host: | tiger.qimr.edu.au | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||